Lee B B
Department of Vascular Surgery, Sungkyunkwan University School of Medicine, Vascular Malformation Clinic, Samsung Medical Center, Seoul 135-710, South Korea.
Eur J Vasc Endovasc Surg. 2005 Aug;30(2):184-97. doi: 10.1016/j.ejvs.2004.10.006.
A retrospective review of the results of management of congenital vascular malformation (CVM) patients was made to assess the efficacy of newly introduced approaches.
CVMs were categorised according to the Hamburg classification on the basis of minimally invasive tests. Invasive studies such as angiography are used to provide a road map for treatment. A new multidisciplinary approach was adopted, which accepts the integration of embolisation and sclerotherapy with traditional surgical therapy. Embolo-sclerotherapy was used as an independent therapy and as an adjunctive therapy to surgery.
Ninety-nine out of a total of 294 venous malformation patients underwent ethanol sclerotherapy with an immediate success rate of 98.8%, requiring 419 sessions of treatment. Interim results were excellent with no evidence of recurrence (mean follow-up 18.2 months). Most of the 25 patients treated surgically received pre-operative embolo-sclerotherapy, each with excellent interim results and minimum morbidity (mean follow-up 21.2 months). Forty-eight patients among 76 arteriovenous malformation patients underwent embolo-sclerotherapy independently (32/48) or adjunctively (16/48). Independent therapy on 32 produced excellent interim results (25/32) requiring a total of 171 sessions (mean follow-up 19.2 months). Eighty-nine extratruncal (ET) forms of lymphatic malformations received multiple sessions of sclerotherapy with OK-432 (108/120 sessions) or ethanol (12/20 sessions). OK-432 was used in 51 paediatric patients with the ET form and produced an excellent response in cystic type lesions (40/45) requiring 61 sessions with no evidence of recurrence (mean follow-up 24.2 months), whereas a mixed result was obtained in the cavernous type (3/6). OK-432 sclerotherapy was used as a pre-operative adjunctive therapy in 7 patients requiring 21 sessions with 17 cavernous type of the ET form, and produced good to excellent results after surgical excision of 14 lesions.
New approaches to the treatment of CVMs based on a multidisciplinary approach can improve results by fully combined surgical treatment with embolo-sclerotherapy.
对先天性血管畸形(CVM)患者的治疗结果进行回顾性分析,以评估新引入方法的疗效。
基于微创检查,根据汉堡分类法对CVM进行分类。血管造影等侵入性检查用于为治疗提供路线图。采用了一种新的多学科方法,该方法接受栓塞和硬化治疗与传统手术治疗的联合应用。栓塞硬化治疗既作为独立治疗方法,也作为手术的辅助治疗方法。
294例静脉畸形患者中有99例接受了乙醇硬化治疗,即刻成功率为98.8%,共进行了419次治疗。中期结果良好,无复发迹象(平均随访18.2个月)。25例接受手术治疗的患者大多在术前接受了栓塞硬化治疗,每例中期结果均良好,且发病率最低(平均随访21.2个月)。76例动静脉畸形患者中有48例独立(32/48)或辅助(16/48)接受了栓塞硬化治疗。对32例进行的独立治疗产生了良好的中期结果(25/32),共进行了171次治疗(平均随访19.2个月)。89例躯干外(ET)型淋巴管畸形接受了多次OK - 432(108/120次)或乙醇(12/20次)硬化治疗。51例ET型儿科患者使用了OK - 432,对囊性病变(40/45)产生了良好反应,共进行了61次治疗,无复发迹象(平均随访24.2个月),而海绵状病变(3/6)的结果不一。OK - 432硬化治疗在7例需要21次治疗的ET型海绵状病变患者中用作术前辅助治疗,在14例病变手术切除后产生了良好至优秀的结果。
基于多学科方法的CVM新治疗方法通过将手术治疗与栓塞硬化治疗充分结合,可改善治疗效果。